In glioblastoma, an increased Treg abundance correlates with decreased T cell cytotoxicity23 and inhibiting CD4+ T cell differentiation into Tregs in immunogenic glioblastoma models potentiates anti-tumor immune response24. This evidence concerns the gene CD4 and glioblastoma.